Literature DB >> 27284023

SYNBIOCHEM-a SynBio foundry for the biosynthesis and sustainable production of fine and speciality chemicals.

Pablo Carbonell1, Andrew Currin1, Mark Dunstan1, Donal Fellows1, Adrian Jervis1, Nicholas J W Rattray1, Christopher J Robinson1, Neil Swainston1, Maria Vinaixa1, Alan Williams1, Cunyu Yan1, Perdita Barran2, Rainer Breitling2, George Guo-Qiang Chen2, Jean-Loup Faulon2, Carole Goble3, Royston Goodacre2, Douglas B Kell2, Rosalind Le Feuvre4, Jason Micklefield2, Nigel S Scrutton5, Philip Shapira6, Eriko Takano7, Nicholas J Turner7.   

Abstract

The Manchester Synthetic Biology Research Centre (SYNBIOCHEM) is a foundry for the biosynthesis and sustainable production of fine and speciality chemicals. The Centre's integrated technology platforms provide a unique capability to facilitate predictable engineering of microbial bio-factories for chemicals production. An overview of these capabilities is described.
© 2016 The Author(s).

Entities:  

Keywords:  biocatalysis; fine chemicals; metabolic engineering; synthetic biology; systems biology

Mesh:

Year:  2016        PMID: 27284023      PMCID: PMC4900749          DOI: 10.1042/BST20160009

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


The Manchester University Synthetic Biology Research Centre (SBRC), SYNBIOCHEM (http://synbiochem.co.uk), is focused on delivering Synthetic Biology (SynBio) solutions that provide innovative, fast, predictable and robust production routes for diverse fine and speciality chemicals underpinned by Responsible Research and Innovation (RRI). By harnessing the power of predictive SynBio methods, SYNBIOCHEM is driving next-generation sustainable manufacturing processes that are appropriate and commercially relevant for scale-up across many industrial sectors (e.g. healthcare, energy, agrichemicals, green chemistry, pharmaceuticals, novel materials and bioremediation). SYNBIOCHEM is located in the Manchester Institute of Biotechnology (MIB; http://www.mib.ac.uk/) and builds on the MIB's core strategy of uniting teams of interdisciplinary scientists and industrial partners to deliver challenge-led innovation in bio-based chemicals and broader industrial biotechnology sectors. SYNBIOCHEM also builds on a long-term vision and commitment by the University of Manchester in sustainable Industrial Biotechnology, leveraging and integrating world-leading capabilities in MIB Centres of Excellence including: Biocatalysis, Biotransformation and Biocatalytic Manufacture (CoEBio3); Manchester Centre for Biophysics and Catalysis (MCBC); Manchester Centre for Integrative Systems Biology (MCISB) and the Michael Barber Collaborative Centre for MS (MBCMS). SYNBIOCHEM was established in 2014 funded jointly by the U.K. Biotechnology and Biological Sciences Research Council, the U.K. Engineering and Physical Sciences Research Council and The University of Manchester. Led by three directors (Nigel Scrutton, Eriko Takano and Nick Turner) the Centre unites a complementary team of SynBio researchers at Manchester in pursuit of SynBio solutions that will deliver wider access to chemical diversity and more rapid and predictable delivery of chemical targets for scalable production/manufacturing. The interdisciplinary team includes not only chemists, biologists and computer scientists, but also investigators from the Manchester Institute of Innovation Research and the School of Social Sciences contributing insight of RRI relevant to the Centre activities. A key challenge includes consideration of the societal impact of SYNBIOCHEM research activities to ensure that the Centre anticipates, prepares for and, if necessary, mitigates the impact of SynBio technology in the wider society, economy and environment [1]. SYNBIOCHEM has established state-of-the-art and fully integrated Design/Build/Test technology platforms for bio-based chemicals production (Figure 1). The platforms include innovative DESIGN platforms for the computational modelling and design of biological parts, devices and chassis; state-of-the-art high-throughput and automated BUILD capabilities for the rapid assembly of engineered microbial systems; and a suite of advanced analytical TEST technologies, including mass spectrometers for sensitive targeted chemical detection and untargeted metabolomics, and picodroplet/fermentation platforms for production and analysis from the single cell through to the 1 l scale. The technology platforms are supported by a comprehensive fully shared standards-compliant data management platform that ranges from laboratory information management system (LIMS) to notebooks to cross project cataloguing that will be openly available. The SYNBIOCHEM platforms are supported by an expert team of Senior Experimental Officers to implement the Centre's science programmes, which are currently focused on the engineering of microbial bio-factories for the sustainable production, scale-up and diversification of terpenoids, flavonoids and alkaloids.
Figure 1

Schematic of the SYNBIOCHEM synthetic biology foundry

Schematic of the foundry concept established in SYNBIOCHEM that enables iterative Design, Build and Test workflows for the engineering of new biological parts (e.g. enzymes and regulatory components), devices (e.g. pathways and cellular compartments) and systems (microbial chassis and processes).

Schematic of the SYNBIOCHEM synthetic biology foundry

Schematic of the foundry concept established in SYNBIOCHEM that enables iterative Design, Build and Test workflows for the engineering of new biological parts (e.g. enzymes and regulatory components), devices (e.g. pathways and cellular compartments) and systems (microbial chassis and processes). SYNBIOCHEM has an open and collaborative culture with a strong emphasis on building academic and industry partnerships, both at the national and international levels. Industrial foresight and awareness coupled to translation of SYNBIOCHEM discovery science and technology towards commercial exploitation are at the core of the Centre's strategy. The Centre hosts regular open meetings in a variety of formats, enabling one-to-one discussions with industrial partners, the development of new collaborative projects with external stakeholders, and through an industry club for joint supervision of research studentships in projects that address scientific problems of interest to the club members. Early SYNBIOCHEM programmes have resulted in protection of new intellectual property for the development of tools and microbial factories/hosts relevant to the production of pravastatin [2], biosynthetic menthol [3] and propane [4], the development of new regulatory components (e.g. riboswitches [5]) and the discovery of new biocatalysts for chemicals production that provide new routes to alkenes [6,7] and enantiopure amines [8]. This is supported by unique technology innovations in DNA design and assembly [9,10] that underpin the rapid construction and evolution of new parts and pathways through, for example new approaches to directed evolution [11]. Many of these discoveries are subject to new SYNBIOCHEM patent submissions and, in one case, have already supported the formation of an early spinout company from the Centre. In summary, SYNBIOCHEM is addressing major challenges in SynBio through a foundry concept and an open collaborative ethos with external partners. The Centre's integrated technology platforms provide a unique capability to facilitate predictable engineering of microbial bio-factories for chemicals production. Further information about the Centre and routes to collaboration can be obtained from the SYNBIOCHEM website: http://synbiochem.co.uk.
  10 in total

1.  GeneGenie: optimized oligomer design for directed evolution.

Authors:  Neil Swainston; Andrew Currin; Philip J Day; Douglas B Kell
Journal:  Nucleic Acids Res       Date:  2014-04-29       Impact factor: 16.971

2.  Single-step fermentative production of the cholesterol-lowering drug pravastatin via reprogramming of Penicillium chrysogenum.

Authors:  Kirsty J McLean; Marcus Hans; Ben Meijrink; Wibo B van Scheppingen; Aad Vollebregt; Kang Lan Tee; Jan-Metske van der Laan; David Leys; Andrew W Munro; Marco A van den Berg
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-17       Impact factor: 11.205

3.  Rational Re-engineering of a Transcriptional Silencing PreQ1 Riboswitch.

Authors:  Ming-Cheng Wu; Phillip T Lowe; Christopher J Robinson; Helen A Vincent; Neil Dixon; James Leigh; Jason Micklefield
Journal:  J Am Chem Soc       Date:  2015-07-09       Impact factor: 15.419

4.  Enzymatic Menthol Production: One-Pot Approach Using Engineered Escherichia coli.

Authors:  Helen S Toogood; Aisling Ní Cheallaigh; Shirley Tait; David J Mansell; Adrian Jervis; Antonios Lygidakis; Luke Humphreys; Eriko Takano; John M Gardiner; Nigel S Scrutton
Journal:  ACS Synth Biol       Date:  2015-06-05       Impact factor: 5.249

5.  A microbial platform for renewable propane synthesis based on a fermentative butanol pathway.

Authors:  Navya Menon; András Pásztor; Binuraj Rk Menon; Pauli Kallio; Karl Fisher; M Kalim Akhtar; David Leys; Patrik R Jones; Nigel S Scrutton
Journal:  Biotechnol Biofuels       Date:  2015-04-10       Impact factor: 6.040

6.  Conversion of alcohols to enantiopure amines through dual-enzyme hydrogen-borrowing cascades.

Authors:  Francesco G Mutti; Tanja Knaus; Nigel S Scrutton; Michael Breuer; Nicholas J Turner
Journal:  Science       Date:  2015-09-25       Impact factor: 47.728

7.  SpeedyGenes: an improved gene synthesis method for the efficient production of error-corrected, synthetic protein libraries for directed evolution.

Authors:  Andrew Currin; Neil Swainston; Philip J Day; Douglas B Kell
Journal:  Protein Eng Des Sel       Date:  2014-08-09       Impact factor: 1.650

Review 8.  Synthetic biology for the directed evolution of protein biocatalysts: navigating sequence space intelligently.

Authors:  Andrew Currin; Neil Swainston; Philip J Day; Douglas B Kell
Journal:  Chem Soc Rev       Date:  2015-03-07       Impact factor: 54.564

9.  New cofactor supports α,β-unsaturated acid decarboxylation via 1,3-dipolar cycloaddition.

Authors:  Karl A P Payne; Mark D White; Karl Fisher; Basile Khara; Samuel S Bailey; David Parker; Nicholas J W Rattray; Drupad K Trivedi; Royston Goodacre; Rebecca Beveridge; Perdita Barran; Stephen E J Rigby; Nigel S Scrutton; Sam Hay; David Leys
Journal:  Nature       Date:  2015-06-17       Impact factor: 49.962

10.  UbiX is a flavin prenyltransferase required for bacterial ubiquinone biosynthesis.

Authors:  Mark D White; Karl A P Payne; Karl Fisher; Stephen A Marshall; David Parker; Nicholas J W Rattray; Drupad K Trivedi; Royston Goodacre; Stephen E J Rigby; Nigel S Scrutton; Sam Hay; David Leys
Journal:  Nature       Date:  2015-06-17       Impact factor: 49.962

  10 in total
  4 in total

Review 1.  Mapping the patent landscape of synthetic biology for fine chemical production pathways.

Authors:  Pablo Carbonell; Abdullah Gök; Philip Shapira; Jean-Loup Faulon
Journal:  Microb Biotechnol       Date:  2016-08-03       Impact factor: 5.813

2.  SYNBIOCHEM Synthetic Biology Research Centre, Manchester - A UK foundry for fine and speciality chemicals production.

Authors:  Le Feuvre Ra; Carbonell P; Currin A; Dunstan M; Fellows D; Jervis Aj; Rattray Njw; Robinson Cj; Swainston N; Vinaixa M; Williams A; Yan C; Barran P; Breitling R; Chen Gg; Faulon Jl; Goble C; Goodacre R; Kell Db; Micklefield J; Scrutton Ns; Shapira P; Takano E; Turner Nj
Journal:  Synth Syst Biotechnol       Date:  2016-08-25

3.  Evolutionary algorithms and synthetic biology for directed evolution: commentary on "on the mapping of genotype to phenotype in evolutionary algorithms" by Peter A. Whigham, Grant Dick, and James Maclaurin.

Authors:  Douglas B Kell
Journal:  Genet Program Evolvable Mach       Date:  2017-03-29       Impact factor: 1.714

Review 4.  Consolidated Bioprocessing: Synthetic Biology Routes to Fuels and Fine Chemicals.

Authors:  Alec Banner; Helen S Toogood; Nigel S Scrutton
Journal:  Microorganisms       Date:  2021-05-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.